Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

7.51
+0.28003.87%
Pre-market: 7.670.1591+2.12%08:01 EDT
Volume:3.90M
Turnover:28.78M
Market Cap:1.64B
PE:-5.31
High:7.57
Open:7.20
Low:7.06
Close:7.23
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:0.94
T/O Rate:2.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:3.16
PE(LYR):-5.29

Loading ...

Ocular Therapeutix™ Announces First Patient Enrolled in Sol-X Long-Term Extension Trial for Axpaxli™ in Wet Amd

THOMSON REUTERS
·
Apr 29

Ocular Therapeutix to report first-quarter results, host conference call and webcast

Reuters
·
Apr 28

Ocular Therapeutix to present at Bank of America Health Care Conference fireside chat

Reuters
·
Apr 27

Assessing Ocular Therapeutix (OCUL) Valuation As AXPAXLI Prospects Drive A Wide Gap To Fair Value Estimates

Simply Wall St.
·
Apr 22

Ocular Therapeutix to host investor day webcast

Reuters
·
Apr 22

Ocular Therapeutix grants inducement equity awards to new hires under 2019 plan

Reuters
·
Apr 14

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune

Reuters
·
Apr 14

Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study

Benzinga_recent_news
·
Apr 14

Ocular Therapeutix Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma

Reuters
·
Apr 13

BUZZ-Ocular Therapeutix rises as new eye drug shows longer disease control

Reuters
·
Apr 13

Ocular Therapeutix posts positive week-52 data from SOL-1 Phase 3 AXPAXLI trial

Reuters
·
Apr 13

Ocular Therapeutix™ Announces Additional Positive Week 52 Data From Landmark Sol-1 Phase 3 Trial of Axpaxli™ in Wet Amd

THOMSON REUTERS
·
Apr 13

Ocular Therapeutix Inc - Axpaxli Meets Statistical Significance in Multiple Secondary Endpoints in Sol-1 Trial

THOMSON REUTERS
·
Apr 13

How Axpaxli Phase 3 Anticipation from Key Ophthalmology Meetings Will Impact Ocular Therapeutix (OCUL) Investors

Simply Wall St.
·
Apr 13